Zeria

Zeria Group’s subsidiary Tillotts Pharma has completed the acquisition of AstraZeneca‘s Entocort (budesonide) global rights outside the US for around $215m.

The deal was announced in the second week of this month.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Entocort is a gastroenterology medicine to treat patients with mild to moderate Crohn’s disease and ulcerative colitis.

As part of the deal, Tillotts has acquired rights to sell and develop Entocort capsules and enema formulations outside the US. The deal will not include the transfer of any AstraZeneca employees or facilities.

In capsule formulation, Entocort is a first-line therapy indicated to induce and maintain clinical remission of mild to moderate active Crohn’s disease involving the ileum and ascending colon.

It is indicated to induce and maintain clinical remission of distal ulcerative colitis in the rectum, sigmoid colon and descending colon in the enema form.

“In capsule formulation, Entocort is a first-line therapy indicated to induce and maintain clinical remission of mild to moderate active Crohn’s disease.”

Entocort is currently commercialised in around 40 countries and reported sales of about $53m outside the US in 2014.

The regulatory submission for Entocort is expected in the coming months in Japan.

AstraZeneca has established partnership with Par Pharmaceutical to commercialise Entocort in the US.

Tillotts Pharma is involved in the development of innovative pharmaceutical products, medical devices and diagnostics in the field of gastroenterology.

The firm markets its own products, including Asacol and Colpermin, as well as VistaPrep and in-licensed products such as Simtomax in around 55 countries through its own subsidiaries.

Image: High-magnification micrograph of Crohn’s disease. Biopsy of colon. H&E stain. Photo: courtesy of Nephron.